🚀 Biotech & Life Sciences Weekly Highlights 🌱

1. Privacy Under Fire: 27 states and D.C. are suing 23andMe to stop the sale of personal genetic data without consent — as Regeneron eyes acquisition during bankruptcy proceedings.
2. Organoid Innovation: Pluristyx launches the PluriForm™ Organoid Kit, dramatically cutting down organoid development timelines with ready-to-differentiate iPSCs.
3. Funding Milestone: Genesys Capital closes its largest fund yet — Genesys Ventures IV LP — backing Canadian life sciences with strong investor confidence.
4. Rare Disease Breakthroughs: Chiesi Group partners with Key2Brain AB to advance blood-brain barrier-crossing therapies for lysosomal storage disorders.
5. Next-Gen Neurotherapeutics: Enveric Biosciences secures a patent for low-hallucinogenic neuroplastogens, opening new doors in psychiatric treatment.

🔍 Stay tuned — innovation is not slowing down!

Sources

• Dozens of states sue to block the sale of 23andMe personal genetic data without customer consent
• Pluristyx Launches PluriForm™ Organoid Kit, Slashing Weeks Off Organoid Development Timelines
• Genesys Capital is Closing its Largest Fund to Date – Genesys Ventures IV LP
• Chiesi Group Enters into Worldwide Licensing Agreement with Key2Brain AB
• Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens
• Five BIO 2025 events you don’t want to miss 
• Layoff Tracker: Gilead Cuts 36 Employees in California 

🚀 This week’s podcast covers a wide range of Biotech updates 🧬

Topics include a new gene-editing therapy used in a rare pediatric case, progress in cell sorting technologies, and recent patent activity in therapeutic development. If you’re looking for a brief, clear summary of what’s happening in the space, this episode offers a helpful overview.

🎧 Listen here. 

#Biotech #LifeSciences #GeneTherapy #CRISPR #Healthcare #IndustryUpdate #Podcast #AI #NotebookLM

Sources:

• Baby saved by gene-editing therapy 'graduates' from hospital, goes home
• STEMCELL Technologies Announces Acquisition of Cellular Highways
• Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds
• Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)
• Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform

Disclaimer: This podcast includes content generated with the help of large language models (LLM). Although care has been taken to ensure accuracy, LLMs can sometimes produce incorrect or misleading information. Listeners are advised to independently verify any details, provide feedback, and reach out.